TAT-11: Astatine-211: The Chemistry Infrastructure

Ottawa, ON, Canada (UroToday.com) Despite the availability of At211 production via Bi209(alpha, 2n)At211 at cyclotrons, alpha therapy research suffers from the lack of a chemical infrastructure for producing an end-product At211-conjugated ligand. Dr. Lindegren described such an automated infrastructure developed at Gothenburg. He also described a clinical trial for treating ovarian cancer with 200 MBq of At211.

Presented by: Sture Lindegren, PhD, Department of Radiation Physics, Gothenburg University, Göteborg, Vaestra Goetaland, Sweden

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada